BRCA1 and hereditary cancer: According to the American Society of Clinical Oncology (ASCO) and Society of Surgical Oncology (SSO) guideline, BRCA1/2 testing should be offered to all women younger than age 65 at the time of BC diagnosis, as well as for all female BC patients who are eligible for PARP inhibitor therapy, have TNBC, have a second contralateral or ipsilateral primary BC, or have a personal or family history suggestive of hereditary cancer.